Medical Xpress August 10, 2024
Ernie Mundell

Folks nervous about administering a rescue shot for anaphylaxis finally have a new alternative in a nasal spray.

The U.S. Food and Drug Administration on Friday announced that it has approved neffy, the first non-injected treatment for life-threatening .

The epinephrine is for use by adults and children who weigh more than 66 pounds, the agency said.

“Anaphylaxis is life-threatening and some people, particularly children, may delay or avoid treatment due to fear of injections,” Dr. Kelly Stone, associate director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluation and Research, said in an agency statement. “The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency

Share This Article